AAN: GLP-1 Receptor Agonist Initiation for Chronic Migraine Tied to Improved Outcomes

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on March 2, 2026.

via HealthDay

MONDAY, March 2, 2026 -- For people with chronic migraine (CM), taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with fewer emergency department visits and hospitalizations overall and less need for medications used to stop and prevent migraine attacks, according to a study scheduled for presentation at the annual meeting of the American Academy of Neurology, to be held from April 18 to 22 in Chicago.

Vitoria Acar, from the University of Sao Paulo in Brazil, and colleagues compared health care utilization, triptan use, and preventive-treatment escalation following initiation of a GLP-1 RA versus topiramate in adults with CM. The analysis included 10,997 adults with CM initiating a GLP-1 RA (liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, or albiglutide) within 12 months of diagnosis, as well as matched adults initiating topiramate.

The researchers found that compared with topiramate, GLP-1 RA initiators had a lower risk for emergency department visits (risk ratio [RR], 0.90), hospitalizations (RR, 0.86), nerve blocks (RR, 0.87), and triptan use (RR, 0.87). GLP-1 RA initiators also had a lower risk for initiation of tricyclic antidepressants (RR, 0.65), valproate (RR, 0.52), gepants (RR, 0.77), calcitonin gene-related peptide monoclonal antibodies (RR, 0.58), and serotonin-norepinephrine reuptake inhibitors (RR, 0.80). For beta-blocker initiation, there were no significant differences observed.

"Seeing these patterns of lower use of emergency care and lower use of drugs to stop migraines or trying additional drugs to prevent migraines among people taking GLP-1 drugs for other conditions suggests that these therapies may help stabilize the disease burden in ways that we haven’t fully appreciated yet," Acar said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-03-03 01:40

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords